The invention discloses application of
alkannin in preparation of drugs for resisting photodermatosis. The shikonin
emulsion is used for external treatment of a constructed
photoaging mouse model, and results show that after the shikonin
emulsion is intervened for one week, mouse epidermis is thickened, namely, the mouse epidermis is recovered to a
normal level, and after the shikonin
emulsion is intervened for 14 days, mouse true dermatitis cells are also close to the
normal level. When the shikonin emulsion intervenes for 7 days,
cuticle pigment is reduced, the density and arrangement of dermal collagenous fibers are obviously improved, and after the shikonin emulsion intervenes for 14 days, the dermal collagenous fibers return to a
normal state. The invention provides an important experimental basis for the treatment of
photoaging by the shikonin emulsion through animal experiments. Furthermore,
clinical tests are carried out, and the result shows that the external shikonin emulsion has a remarkable
treatment effect on human actinic dermatitis clinically. Therefore, the invention provides a novel therapeutic
drug and scheme for prevention and treatment of photodermatosis, and has good clinical application prospects and high clinical application values.